Dr Jared Silverman
Microbiology
AUSPHERIX
New Zealand
Biography
Non-Executive Director Dr Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. US-based, he is currently VP of Research at Kaleido Biosciences, following 18 years at Cubist Pharmaceuticals where he contributed to the discovery of three novel antibiotics that entered clinical development, including as the biology lead for the discovery of Surotomycin, currently in Phase 3 trials for the treatment of C. difficile. Additionally, Dr Silverman and his collaborators pursued studies into the mechanism of action of the lipopeptide antibiotic daptomycin and the mechanisms of resistance to this clinically important antibiotic. He undertook postdoctoral training at Yale University and has a PhD in Microbiology from Harvard Medical School. Dr. Silverman serves as a member of the UK MRC’s Antimicrobial Resistance steering group.
Research Interest
Microbiology
